Company news

Daiichi Sankyo Company, Limited (TSE:4568) news

Every Daiichi Sankyo Company, Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.

Daiichi Sankyo Company, Limited (TSE:4568) news

Press releases & updates

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients...

Daiichi Sankyo : Receives Favorable Judgment in Damage Claim Filed by NTK

(Modification of Disclosed Matter) Notice Regarding Change in the Effective Date of the Absorption-type Merger of Daiichi Sankyo with Its...

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of...

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovati...

(Re-correction) "Reference Data for FY2025 Consolidated Financial Results"

(Correction) Partial Correction of "Financial Results for the Fiscal Year Ended March 31, 2026 [IFRS] (Consolidated)"

Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Own Shares as Restricted Share-Based Compensation

Daiichi Sankyo Announces Disposal of Own Shares as Medium-Term Performance-Based Share Compensation for Company’s Directors and Corporate...

Daiichi Sankyo Announces Disposal of Own Shares as Restricted Share-Based Compensation

Notice Regarding the Conclusion of a Money Loan Agreement with Financial Covenants

Daiichi Sankyo : Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML

Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta® in Newly Diagnosed FLT3-ITD Positive AML

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Tripl...

Daiichi Sankyo : Participation in WHO-GBCI Phase 2 through a Partnership with City Cancer Challenge (C/Can) — Contributing to Breast Canc...

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Daiichi Sankyo : Announces Occurrence of Losses Related to Review of Product Supply Plans and Revision of Consolidated Financial Forecast...

Daiichi Sankyo Announces Rescheduling of the Announcement of Consolidated Financial Results for Year Ended March 31, 2026

Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies

Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase

4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Canc...

ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metasta...

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across...

Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discov...

Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activat...

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.

SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negat...

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are ...

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metasta...

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non...

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Ca...

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast C...

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2...